182 related articles for article (PubMed ID: 7906608)
1. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
Singleton TP; Perrone T; Oakley G; Niehans GA; Carson L; Cha SS; Strickler JG
Cancer; 1994 Mar; 73(5):1460-6. PubMed ID: 7906608
[TBL] [Abstract][Full Text] [Related]
2. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
Noske A
Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
4. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
6. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients].
Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438
[TBL] [Abstract][Full Text] [Related]
7. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
8. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
[TBL] [Abstract][Full Text] [Related]
9. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
11. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
12. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
[TBL] [Abstract][Full Text] [Related]
13. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
14. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer.
Kodama J; Miyagi Y; Seki N; Tokumo K; Yoshinouchi M; Kobashi Y; Okuda H; Kudo T
Eur J Obstet Gynecol Reprod Biol; 1999 Jan; 82(1):107-10. PubMed ID: 10192497
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma.
Tanner B; Kreutz E; Weikel W; Meinert R; Oesch F; Knapstein PG; Becker R
Gynecol Oncol; 1996 Aug; 62(2):268-77. PubMed ID: 8751560
[TBL] [Abstract][Full Text] [Related]
16. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture.
Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Suzuki T; Ino K; Kawai M; Mizutani S
Oncology; 2003; 65(1):29-36. PubMed ID: 12837980
[TBL] [Abstract][Full Text] [Related]
18. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
19. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
20. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
